AHA slides: Rivaroxaban users more likely to stay on therapy

Researchers reported Nov. 19 at the American Heart Association scientific session in Dallas that at three months 85 percent of patients with nonvalvular atrial fibrillation treated with rivaroxaban had continued to take the anticoagulant compared with 76 percent of patients on warfarin.

The real-world study was designed to compare the effectiveness, safety and persistence in use of rivaroxaban (Xarelto, Janssen Pharmaceuticals/Bayer HealthCare) and warfarin in patients with atrial fibrillation who are at risk of stroke and systemic embolism. The study found no significant difference in effectiveness and safety and showed the risk of treatment discontinuation was lower for rivaroxaban.

Winnie W. Nelson of Janssen presented the findings. Janssen funded the study.


 

Aos 213 01 nelson rivaroxaban effectiveness and safety in nvaf final from Trimed Media Group
Candace Stuart, Contributor

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup